Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Tecan Group AG's enterprise value is CHF2,359.7 Mil.
Tecan Group AG's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was CHF-37.1 Mil. Therefore, Tecan Group AG's EV-to-EBITDA for today is -63.57.
The historical rank and industry rank for Tecan Group AG's EV-to-EBITDA or its related term are showing as below:
LTS:0QLN'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -63.59 Med: 21.63 Max: 45.18
Current: -63.59
During the past 13 years, the highest EV-to-EBITDA of Tecan Group AG was 45.18. The lowest was -63.59. And the median was 21.63.
LTS:0QLN's EV-to-EBITDA is ranked worse than 100% of 512
companies
in the Medical Devices & Instruments industry
Industry Median: 14.485
vs LTS:0QLN: -63.59
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Tecan Group AG (LTS:0QLN) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Tecan Group AG's PE Ratio (TTM) for today is calculated as:
Tecan Group AG's share price for today is CHF194.60292.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Tecan Group AG's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was CHF-8.740.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Tecan Group AG's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0QLN vs ISRG, BDX, MDLN: EV-to-EBITDA Comparison
For the Medical Instruments & Supplies subindustry, Tecan Group AG's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tecan Group AG EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Tecan Group AG's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Tecan Group AG's EV-to-EBITDA falls into.
Tecan Group AG's current Enterprise Value is CHF2,359.7 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Tecan Group AG's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was CHF-37.1 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tecan Group AG (LTS:0QLN) has a EV-to-EBITDA of -63.57 as of Aug. 05, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Tecan Group AG. According to the industry distribution chart, Tecan Group AG ranks #999999 out of 512 companies in the Medical Devices & Instruments industry.
Is Tecan Group AG's EV-to-EBITDA too high?
Tecan Group AG's current EV-to-EBITDA is -63.57. Based on the distribution chart, Tecan Group AG ranks #999999 out of 512 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Tecan Group AG has a GF Score™ of 76/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Tecan Group AG's EV-to-EBITDA compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Tecan Group AG ranks #999999 out of 512 companies for EV-to-EBITDA. This places Tecan Group AG in the lower half of its industry. The industry median EV-to-EBITDA is 14.49. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.49, based on 512 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Tecan Group AG. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tecan Group AG's current EV-to-EBITDA is -63.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tecan Group AG stock overvalued right now?
Based on GuruFocus' analysis, Tecan Group AG (LTS:0QLN) is currently considered Modestly Undervalued. The stock's GF Value™ is CHF243.78, compared to a current price of CHF194.60 — trading 20.2% below its estimated fair value. The current EV-to-EBITDA is -63.57. Tecan Group AG's overall GF Score™ is 76/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Tecan Group AG (LTS:0QLN), the current EV-to-EBITDA is -63.57 as of Aug. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tecan Group AG (LTS:0QLN) Overvalued in 2026?
Based on GuruFocus' analysis, Tecan Group AG stock appears to be undervalued.
The current stock price of CHF194.60 is trading 20.2% below its estimated GF Value™ of CHF243.78.
GuruFocus considers Tecan Group AG to be Modestly Undervalued.
Key valuation signals for LTS:0QLN:
EV-to-EBITDA: -63.57
GF Value™: CHF243.78 vs. price of CHF194.60 (20.2% below fair value)
No single metric tells the full story. See the LTS:0QLN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tecan Group AG sells automated laboratory instruments and solutions for the diagnostics and life sciences research markets. The firm operates in two segments; The Life Sciences Business (end-customer business) segment supplies end users with automated workflow solutions directly. These solutions include laboratory instruments, software packages, application know-how, services, consumables, and spare parts, The partnering Business (OEM business) segment develops and manufactures OEM instruments and components that are distributed by partner companies under their names. A majority proportion of Tecan's revenue is generated in the Americas and Europe followed by Asia Specific.
76GF Score
Get the complete analysis for LTS:0QLN
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0QLN has been successfully added to your 
